Yair Einhorn(@yaireinhorn) 's Twitter Profileg
Yair Einhorn

@yaireinhorn

#Science & #Innovation. Special interest in #CRISPR, #GeneEditing, #GeneTherapy 🧬 & #Ophthalmology. #Biotech, #Markets & #Stocks 📈

ID:1238780417324580867

calendar_today14-03-2020 10:54:12

4,3K Tweets

3,8K Followers

34 Following

Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

Thank you dear friend for your kind words and endorsement. I always try to bring the most interesting and up to date information regarding , & & will continue to do so. You are truly one of a kind! 🙏 Disruptor ⚡️

account_circle
Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

That was in response to a question about the company’s pipeline - referring I guess to Editas Medicine recent decision to terminate $EDIT-101 and the brilliance clinical trail👇

account_circle
Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

An interesting remark was made by Gilmore O’Neill - Editas Medicine’s CEO about his intention of “refocus the pipeline by focusing on advancing $EDIT-301 but not on the expense of current pipeline” - which I guess are $EDIT-103 for & $EDIT-202 for solid

account_circle
Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

8/It might take a little more time than initially expected but the vector is clear - like any revolutionary concept In-Vivo will eventually be approved. I’m confident in the ability of Sek Kathiresan MD and the entire Verve Therapeutics team to deliver. It’s only a matter of time!

account_circle